MiniMed Lifts FY27 Organic Growth Outlook to 10.5% After Strong Q1 Beat
MMED sits 86% above its 52-week low of $10.65 on elevated volume (2.0× avg).
Summary
MiniMed beat Q1 FY27 expectations with 16.6% reported revenue growth and raised full-year organic growth guidance to 10.5%, while advancing multiple pipeline milestones ahead of schedule.
Key Events · Earnings and Guidance · MMED
-
Q1 FY27 Revenue Beat
Net sales of $843 million grew 16.6% reported and 15.8% organic, ahead of expectations. U.S. sales grew 13.1% to $240 million; international grew 18.1% to $603 million.
-
FY27 Guidance Raised
Organic revenue growth guidance raised to approximately 10.5% from 10%, including a 1.0-1.5% benefit from the extra week in Q1. Adjusted EBITDA margin guidance of approximately 16% reaffirmed.
-
Pipeline Milestones Ahead of Schedule
FDA submission for MiniMed Fit patch pump completed ahead of Fall target; MiniMed Flex received CE Mark ahead of year-end target; Vivera pivotal trial enrollment complete; next-gen extended wear sensor IDE approved.
-
U.S. Growth Acceleration
U.S. New Pumps Sold grew over 20% year over year, driven by MiniMed Flex and new sensor launches. Worldwide NPS of ~34,000 grew 7.7% year over year; CGM attachment rate reached 69%, up ~100 bps quarter over quarter.
Analysis · MMED · Industrial Applications And Services
MiniMed delivered Q1 FY27 net sales of $843 million, up 16.6% reported and 15.8% organic, beating expectations on accelerating U.S. growth. Management raised full-year organic revenue growth guidance to approximately 10.5% from 10%, while reaffirming adjusted EBITDA margin at 16%. The quarter also brought several pipeline milestones ahead of schedule: FDA submission for the MiniMed Fit patch pump, CE Mark for MiniMed Flex, completed enrollment in the Vivera pivotal trial, and IDE approval for the next-gen extended wear sensor. The company is executing on its innovation roadmap faster than planned, which supports the raised outlook.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.8% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MMED was trading at $19.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $10.65 to $20.88. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.